Ipsen Appoints Peter Guenter to the Board of Directors
Ipsen announces the co-option of Peter Guenter as a board member effective from January 28, 2026, filling the vacancy created by the departure of Henri Beaufour.
Peter Guenter has been co-opted to Ipsen's Board of Directors starting January 28, 2026, following the vacancy left by Henri Beaufour. With this co-option, Ipsen's Board now consists of 14 directors: seven women and seven men, including five independent directors and two representing employees. This decision will be subject to ratification at the next General Shareholders' Meeting and, once approved, will be effective for the remainder of Henri Beaufour's term, until the 2027 General Shareholders' Meeting.
Professional Background
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Peter Guenter brings nearly 40 years of executive experience in the global pharmaceutical industry. He served as the CEO of Merck Healthcare and was a member of Merck Group's Executive Committee from 2021 to 2025. Previously, he was the CEO of Almirall starting in 2017, where he led the company's strategic realignment towards medical dermatology. He also spent over 20 years at Sanofi, holding various leadership positions and joining the Executive Committee in 2013. Peter Guenter actively contributes to various boards in the healthcare and private equity sectors.
SectorSanté · Vaccins et laboratoires de recherche›Industrie Pharmaceutique
Context
Period
Period: 1T2026
Key reported figures
Revenue: 1074.9M€
Guidance from the release
Ipsen a réalisé un excellent début d'année 2026.
Croissance soutenue grâce aux trois aires thérapeutiques.
Risks mentioned
pression réglementaire anticipée sur de nouveaux médicaments
concurrence accrue sur Somatuline à cause des génériques
Opportunities identified
croissance des ventes totales du Groupe supérieure à 13,0 %
lancement de trois nouveaux programmes en phase avancée
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
